Lv2
160 积分 2025-06-02 加入
BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study
1个月前
已完结
Induced proximity pushes beyond protein degraders, as first RIPTAC moves into the clinic
3个月前
已完结
FDA’s New Plausible Mechanism Pathway
3个月前
已完结
Diagnostic Accuracy of the Second Edition of the Paris System for Reporting High-Grade Urothelial Carcinoma in Urinary Cytology
4个月前
已完结
The 2022 World Health Organization Classification of Tumors of the Urinary System and Male Genital Organs—Part B: Prostate and Urinary Tract Tumors
4个月前
已完结
Induced proximity pushes beyond protein degraders, as first RIPTAC moves into the clinic
5个月前
已完结
Efficacy and Safety of BL-B01D1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma: A Phase II Clinical Trial
6个月前
已完结
International Bladder Cancer Group Consensus Statement on Clinical Trial Design for Patients with Bacillus Calmette-Guérin–exposed High-risk Non–muscle-invasive Bladder Cancer
6个月前
已完结
Optimizing Clinical Trial Design for Patients with Non–muscle-invasive Bladder Cancer
6个月前
已完结
Clinical trial design for non-muscle-invasive bladder cancer
6个月前
已完结
皖公网安备34019202002308
